`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner
`
`v.
`
`QUALICAPS CO. LTD.
`Patent Owner
`
`Case IPR2017-00203
`Patent No. 6,649,180
`
`
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S REQUEST FOR
`ORAL ARGUMENT
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT LIST
`
`Exhibit No. Description
`1001
`United States Patent No. 6,649,180
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`Complaint, Warner Chilcott (US), LLC et al. v. Mylan
`Pharmaceuticals, Inc., et al., Case No. 2:15-cv-01740-JRG-RSP
`(E.D. Texas)
`
`Proof of Service of Complaint, Case No. 2:15-cv-01740-JRG-
`RSP (E.D. Texas)
`
`United States Patent No. 5,756,123 (“Yamamoto”)
`
`The Japanese Pharmacopeia (The Society of Japanese
`Pharmacopeia, 13th ed. 1996) (“Japanese Pharmacopeia”)
`
`United States Patent No. 3,493,407 (“Greminger”)
`
`21 C.F.R. § 172.874 (1998)
`
`National Formulary (American Pharmaceutical Association,
`12th ed. 1965)
`
`Handbook of Pharmaceutical Excipients (1986)
`
`File History of United States Patent No. 6,649,180
`
`Expert Declaration of Arthur H. Kibbe
`
`Shin-Etsu Chemical Co., Ltd. PHARMACOAT Technical
`Information Shin-Etsu Chemical Co., Ltd. TC-5 Technical
`Information
`
`Chichester, C.O., E.M. Mrak, and G.F. Stewart, “Utilization of
`Synthetic Gums in the Food Industry,” Advances in Food
`Research, Volume 12, Technical Center, General Foods
`
`ii
`
`
`
`
`
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`Corporation, Tarrytown, N.Y., 1963.
`
`Deposition Transcript of Jason T. McConville, Ph.D., Case No.
`2:15-cv-1471-JRG-RSP (E.D. Tex.), July 8, 2016
`Declaration Of Mr. Jonathan D. Olinger In Support Of
`Petitioner’s Unopposed Motion For Pro Hac Vice Admission
`Under 37 C.F.R. § 42.10(C)
`United States Patent No. 5,756,123 (“Yamamoto”) (Served but
`not filed, June 14, 2017)
`
`The Japanese Pharmacopeia (The Society of Japanese
`Pharmacopeia, 13th ed. 1996) (“Japanese Pharmacopeia”)
`(Served but not filed, June 14, 2017)
`
`21 C.F.R. § 172.874 (1998) (Served but not filed, June 14, 2017)
`
`National Formulary (American Pharmaceutical Association,
`12th ed. 1965) (Served but not filed, June 14, 2017)
`
`Handbook of Pharmaceutical Excipients (1986) (Served but not
`filed, August 11, 2017)
`
`Email exchange between counsel July 25, 2017 (Served but not
`filed, August 11, 2017)
`
`Email exchange between counsel August 4, 2017 (Served but not
`filed, August 11, 2017)
`
`Email exchange between counsel August 10, 2017 (Served but
`not filed, August 11, 2017)
`Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, and
`Mylan Inc.’s Amended Notice Of Videotaped Deposition Of
`Representative(s) Of Qualicaps Co., Ltd. Pursuant To Federal
`Rule Of Civil Procedure 30(B)(6) (Served but not filed, August
`11, 2017)
`Email exchange between counsel March 21, 2017 (Served but
`not filed, August 11, 2017)
`
`Email exchange between counsel April 25, 2017 (Served but not
`filed, August 11, 2017)
`
`iii
`
`
`
`
`
`
`1027
`
`1028
`
`1029
`
`Amended Docket Control Order, Warner Chilcott (US), LLC v.
`Teva Pharmaceuticals USA, Inc., No. 2:15-cv-1471 (E.D. Tex.
`May 19, 2017), ECF No. 165 (Served but not filed, August 11,
`2017)
`
`Deposition Transcript of Jason T. McConville, Ph.D., August 17,
`2017
`
`Reply Expert Declaration of Arthur H. Kibbe
`
`iv
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.70(a) and the Board’s Amended Scheduling
`
`Order (Paper No. 42), Petitioner Mylan Pharmaceuticals Inc. respectfully submits
`
`this Request for Oral Argument. As set forth in the Amended Scheduling Order,
`
`the Board has scheduled oral argument for January 25, 2018. Paper No. 42, at 1.
`
`Petitioner specifies the following issues to be argued:
`
`
`
`Claims 1 and 4 of the ’180 Patent are not patentable as obvious in
`
`view of Ex. 1004 United States Patent No. 5,756,123 (“Yamamoto”) in
`
`combination with Ex. 1005 The Japanese Pharmacopeia (The Society of Japanese
`
`Pharmacopeia, 13th ed. 1996) (“Japanese Pharmacopeia”);
`
`
`
`Any other issues identified by Patent Owner for oral argument or any
`
`other issues raised in papers yet to be filed; and
`
`
`
`Any other issues the Board deems necessary for issuing a final written
`
`decision.
`
`Petitioner requests permission to use audio/visual equipment at the oral
`
`argument,
`
`including a projector and screen for displaying evidence or
`
`demonstrative exhibits.
`
`Respectfully submitted,
`
`Dated: December 6, 2017
`
`
`
`
`Respectfully submitted,
`
`By: s/Mitchell G. Stockwell
`Mitchell G. Stockwell
`Registration No. 39,389
`Lead Counsel for Petitioner
`
`
`
`1
`
`
`
`
`
`
`Lead Counsel
`Mitchell G. Stockwell
`Reg. No. 39,389
`mstockwell@kilpatricktownsend.com
`Kilpatrick Townsend & Stockton LLP
`1100 Peachtree Street, NE
`Suite 2800
`Atlanta, Georgia 30309
`(404) 815 6500
`
`Back-Up Counsel
`D. Clay Holloway
`Reg. No. 58,011
`cholloway@kilpatricktownsend.com
`Kilpatrick Townsend & Stockton LLP
`1100 Peachtree Street, NE
`Suite 2800
`Atlanta, Georgia 30309
`(404) 815 6500
`
`2
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that on December 6, 2017 a copy of the
`
`foregoing Petitioner Mylan Pharmaceuticals Inc.’s Request for Oral Argument was
`
`served by electronic mail by agreement of the parties on the following counsel of
`
`record for Patent Owner.
`
`Jessica L. Parezo (jparezo@cov.com)
`Andrea G. Reister( areister@cov.com)
`Scott E. Kamholz (skamholz@cov.com)
`Michael N. Kennedy (mkennedy@cov.com)
`Megan P. Keane (mkeane@cov.com)
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`
`MaryAnne Armstrong (maa@bskb.com)
`Lynde F. Herzbach (lynde.herzbach@bskb.com)
`Birch, Stewart, Kolasch & Birch, LLP
`8110 Gatehouse Road, Suite 100 East
`Falls Church, VA 22042
`
`
`
`
`Dated: December 6, 2017
`
`
`
`By: s/Mitchell G. Stockwell
`Mitchell G. Stockwell
`Registration No. 39,389
`Lead Counsel for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`